RevOpsis Therapeutics, a US biopharmaceutical company involved in ophthalmic therapies, announced on Tuesday that it has received a Small Business Innovation Research (SBIR) grant of more than USD1.8m from the National Eye Institute (NEI), a division of the National Institutes of Health (NIH).
This grant will fund critical research and development (R&D) activities, including multidose GMP toxicology studies in nonhuman primates, for the company's lead asset, RO-104, a first-in-class fully human modular trispecific biologic designed to address multiple pathways implicated in retinal vascular disease progression. RO-104 offers the potential to address significant unmet needs in the treatment of neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR) and retinal vein occlusions (RVO).
These studies will enable the IND application for RO-104 in preparation for its advancement into first in human clinical trials in late 2025.
The SBIR programme is a competitive federal R&D initiative designed to support small businesses to conduct R&D with strong potential for addressing significant unmet needs and commercialisation. The grant provides RevOpsis with non-dilutive financing to accelerate its efforts to bring innovative therapies for ophthalmic diseases to market.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline